GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: afabicin desphosphono | AFN-1252 | AFN-12520000 | DEBIO-1452 | DEBIO1452
Compound class:
Synthetic organic
Comment: DEBIO 1452 (previously AFN-1252) is the active metabolite of afabicin (DEBIO 1450) [3]. It is an inhibitor of bacterial Fabl, the NADH-dependent enoyl reductase from the type II bacterial fatty acid biosynthesis pathway (FAS-II) [1-2]. It specifically targets staphylococci without significant activity against other Gram +ve or Gram -ve species [2].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| The prodrug (afabicin) has been evaluated as an antibacterial for skin, bone and joint infections. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00014690 | ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | Phase 2 Interventional | National Cancer Institute (NCI) | ||